Guilherme Nader Marta: The impact of low levels of HER2 expression in the Ph3 PALLAS trial

Guilherme Nader Marta, Clinical Fellow at Dana-Farber Cancer Institute, recently shared about the Ph3 PALLAS trial. Read his post on LinkedIn below:

”Proud to share our study looking at the impact of low levels of HER2 expression (HER2-low) in the Ph3 PALLAS trial, including data from >5,300 patients with early ER+ breast cancer enrolled globally.

Geographic variability in HER2-low prevalence was seen across continents, with North America (63%) showing higher rates than Europe and other regions (53%).

This variability extended across countries (17-76%) and even between different sites within a single country. No significant difference in outcomes or palbociclib benefit between patients with HER2-low and HER2-0 tumors.”

Read further.

More posts featuring Guilherme Nader Marta.